MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2024.113973

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2024

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.

Haakensen Vilde Drageset, Öjlert Åsa Kristina, Thunold Solfrid, Farooqi Saima, Nowak Anna K, Chin Wee L, Grundberg Oscar, Szejniuk Weronika Maria, Cedres Susana, Sørensen Jens Benn, Dalen Tonje Sofie, Lund-Iversen Marius, Bjaanæs Maria, Helland Åslaug

Рандомизированное исследованиеКлиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM).

METHODS

In this phase 2 open-label trial, patients with PM progressing after first-line chemotherapy were randomised to receive ipilimumab and nivolumab alone (arm B) or combined with UV1 (arm A). The primary endpoint was progression-free survival (PFS) as determined by BICR. It was estimated that 69 PFS events were needed to detect a hazard ratio (HR) of 0.60 with 80% power and a one-sided alpha level of 0.10.

RESULTS

118 patients were randomised. The median PFS determined by blinded independent central review (BICR) was 4.2 months (95%CI 2.9-9.8) in arm A and 4.7 months (95%CI 3.9-7.0) in arm B (HR 1.01, 80%CI 0.75-1.36 P = 0.979), after a median follow-up of 12.5 months (95%CI 9.7-15.6). The investigator-determined median PFS was 4.3 months (95%CI 3.0-6.8) in arm A and 2.9 months (95%CI 2.4-5.5) in arm B (HR 0.60, 80%CI 0.45-0.81 P = 0.025). Confirmed objective response rate (ORR) by BICR was 31% in arm A and 16% in arm B (odds ratio 2.44 80%CI 1.35-4.49 P = 0.056). After a median follow-up time of 17.3 months (95%CI 15.8-22.9), the OS was 15.4 months (95%CI 11.1-22.6) in arm A and 11.1 months (95%CI 8.8-18.1) in arm B, (HR 0.73, 80%CI 0.53-1.0, P = 0.197).

CONCLUSION

The primary endpoint was not met. Predefined analyses of response rates are in favour of adding the vaccine.

Для цитирования: Haakensen Vilde Drageset, Öjlert Åsa Kristina, Thunold Solfrid, Farooqi Saima, Nowak Anna K, Chin Wee L, Grundberg Oscar, Szejniuk Weronika Maria, Cedres Susana, Sørensen Jens Benn, Dalen Tonje Sofie, Lund-Iversen Marius, Bjaanæs Maria, Helland Åslaug. UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.. European journal of cancer (Oxford, England : 1990). 2024. DOI: 10.1016/j.ejca.2024.113973.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.